ENDRA Life Sciences Inc. (NDRA) Stock Analysis and Metrics

ENDRA Life Sciences

NASDAQ: NDRA

$5.50 ▼ -0.11 (-1.96%)

At close: Jul 13, 2026 · 4:00 PM UTC

Financial Ratios

Market Cap5.95 Mn

P/E-0.81

Div. Yield0.00

Add ratio to table…

About

ENDRA Life Sciences Inc. develops a next-generation enhanced ultrasound technology platform called Thermo-Acoustic Enhanced Ultrasound (TAEUS). The company focuses on using TAEUS to measure liver fat as a biomarker for metabolic diseases and to support the management of GLP-1 receptor agonist therapies. Its goal is to provide an accurate, simple-to-use, inexpensive point-of-care test that functions like a blood pressure cuff for metabolic health assessment. Beyond liver fat measurement, the TAEUS platform is being developed for temperature monitoring during thermoablative procedures, vascular imaging, and tissue perfusion assessment. The company also envisions using TAEUS to support therapeutic monitoring in cardiology and oncology applications.

The company intends to generate revenue primarily through a low barrier-to-entry multi-year subscription-based model that delivers monthly recurring revenue. It will retain a traditional direct product sale option accompanied by annual upgrade and maintenance fees for customers who prefer that approach. In either model, sales are executed by a direct sales force that leverages clinical data from established reference sites to demonstrate value. Additionally, ENDRA plans to license its TAEUS technology to original equipment manufacturers for integration into their ultrasound and thermoablative systems. Revenue from licensing agreements is expected to include upfront fees and ongoing royalties based on sales of incorporated systems.

ENDRA operates in the competitive medical diagnostics ultrasound market where it faces established players such as GE Healthcare, Royal Philips, Siemens Healthineers, Canon Corporation, and Fujifilm Corporation. These competitors offer conventional ultrasound, MRI, and CT systems that dominate imaging markets but lack the specific tissue composition and temperature measurement capabilities of TAEUS. The company's competitive advantage lies in its proprietary thermoacoustic technology which enables ultrasound systems to differentiate fat from lean tissue, monitor tissue temperature in real time, visualize blood vessels with a saline contrast agent, and assess tissue perfusion without ionizing radiation. By providing these functions as an add-on to existing ultrasound scanners, ENDRA aims to deliver a cost-effective, point-of-care alternative to expensive MRI scans and invasive biopsies for liver fat assessment and related applications. This combination of lower cost, point-of-care usability, and absence of radiation exposure positions ENDRA to capture share in markets where traditional imaging is impractical or prohibitively expensive.

The company’s customer base consists of pharmaceutical companies and contract research organizations that require liver fat biomarkers for GLP-1 drug trials, high-end primary care networks seeking advanced metabolic health screening, bariatric and metabolic clinics managing obesity and related disorders, and broad primary and internal medicine providers focused on disease prevention and therapy monitoring. While the filing does not disclose specific customer names, these groups represent the primary ENDRA targets for its TAEUS liver device and future platform applications. ENDRA also anticipates serving specialized users such as interventional radiologists and surgical oncologists who require real-time temperature guidance during ablation therapies.

Investment Thesis

▲ Bull case

ENDRA Life Sciences is positioned to capitalize on a significant structural shift in the diagnostic landscape for steatotic liver disease, where its TAEUS Liver technology offers MRI-PDFF-level accuracy at a fraction of the cost and with point-of-care accessibility, addressing a critical unmet need for over two billion people globally affected by MASLD. The recent multi-site clinical validation demonstrating a 0.90 correlation with MRI-PDFF and consistent performance across diverse populations and operators provides strong evidence that the technology can deliver reliable, standardized liver fat quantification outside of specialized imaging centers, which could accelerate adoption in primary care settings and community clinics where the majority of at-risk patients currently lack access to diagnostic monitoring. This capability is particularly valuable as new metabolic therapies enter the market, creating demand for frequent, affordable monitoring of treatment response that MRI cannot sustainably support due to cost and accessibility constraints, positioning TAEUS Liver as an essential tool for both clinical practice and pharmaceutical trial endpoints.
The company’s strategic alternatives review process, initiated by the Board and advised by Lucid Capital Management, presents a tangible catalyst for value realization that the market may be underestimating, as it opens pathways beyond organic growth including potential mergers, strategic investments, or asset sales that could accelerate commercialization or provide liquidity for shareholders. Given ENDRA’s limited cash runway of approximately $356,000 in cash and cash equivalents as of Q1 2026, coupled with a history of operating losses and reliance on digital asset treasury holdings ($2.4 million), the market may be pricing in a high probability of dilution or distress, yet the formal review process suggests active exploration of value-maximizing transactions that could include partnerships with larger diagnostic or medical device firms seeking to integrate TAEUS technology into their platforms, thereby de-risking the commercial path and potentially providing non-dilutive funding or outright acquisition premiums.
ENDRA’s financial discipline and improving operational efficiency, evidenced by a decrease in cash used in operations from $1.3 million to $1.1 million year-over-year in Q1 2026 despite increased investment in clinical learnings and stock compensation, reflect a management team focused on extending runway while advancing critical milestones, with the reduction in operating cash burn occurring alongside meaningful technical validation that de-risks the technology’s regulatory and clinical viability. The company’s ability to generate unrealized gains from its digital asset treasury ($738,177 in Q1 2026) further supplements its capital strategy, providing non-operational liquidity that reduces immediate financing pressure and allows continued investment in regulatory milestones without compromising core development, a factor that may be overlooked by investors focused solely on GAAP net loss while underestimating the flexibility afforded by its hybrid capital approach.

ENDRA Life Sciences is positioned to capitalize on a significant structural shift in the diagnostic landscape for steatotic liver disease, where its TAEUS Liver technology offers MRI-PDFF-level accuracy at a fraction of the cost and with point-of-care accessibility, addressing a critical unmet need for over two billion people globally affected by MASLD. The recent multi-site clinical validation demonstrating a 0.90 correlation with MRI-PDFF and consistent performance across diverse populations and operators provides strong evidence that the technology can deliver reliable, standardized liver fat quantification outside of specialized imaging centers, which could accelerate adoption in primary care settings and community clinics where the majority of at-risk patients currently lack access to diagnostic monitoring. This capability is particularly valuable as new metabolic therapies enter the market, creating demand for frequent, affordable monitoring of treatment response that MRI cannot sustainably support due to cost and accessibility constraints, positioning TAEUS Liver as an essential tool for both clinical practice and pharmaceutical trial endpoints.
The company’s strategic alternatives review process, initiated by the Board and advised by Lucid Capital Management, presents a tangible catalyst for value realization that the market may be underestimating, as it opens pathways beyond organic growth including potential mergers, strategic investments, or asset sales that could accelerate commercialization or provide liquidity for shareholders. Given ENDRA’s limited cash runway of approximately $356,000 in cash and cash equivalents as of Q1 2026, coupled with a history of operating losses and reliance on digital asset treasury holdings ($2.4 million), the market may be pricing in a high probability of dilution or distress, yet the formal review process suggests active exploration of value-maximizing transactions that could include partnerships with larger diagnostic or medical device firms seeking to integrate TAEUS technology into their platforms, thereby de-risking the commercial path and potentially providing non-dilutive funding or outright acquisition premiums.
ENDRA’s financial discipline and improving operational efficiency, evidenced by a decrease in cash used in operations from $1.3 million to $1.1 million year-over-year in Q1 2026 despite increased investment in clinical learnings and stock compensation, reflect a management team focused on extending runway while advancing critical milestones, with the reduction in operating cash burn occurring alongside meaningful technical validation that de-risks the technology’s regulatory and clinical viability. The company’s ability to generate unrealized gains from its digital asset treasury ($738,177 in Q1 2026) further supplements its capital strategy, providing non-operational liquidity that reduces immediate financing pressure and allows continued investment in regulatory milestones without compromising core development, a factor that may be overlooked by investors focused solely on GAAP net loss while underestimating the flexibility afforded by its hybrid capital approach.

▼ Bear case

ENDRA Life Sciences faces severe near-term liquidity constraints that threaten its ability to sustain operations long enough to achieve commercialization, with only $356,000 in cash and cash equivalents as of March 31, 2026, representing less than four months of operating cash burn at the Q1 2026 run rate of approximately $1.1 million per quarter, a situation exacerbated by the company’s history of recurring losses and limited commercial experience, which raises substantial doubt about its capacity to obtain adequate financing on favorable terms without significant dilution or restrictive covenants that could impair shareholder value.
Despite promising clinical validation data, ENDRA’s TAEUS Liver technology remains subject to significant regulatory and commercialization risks, including the potential for delays or changes in FDA requirements, the uncertainty of obtaining and maintaining CE mark certifications, and the challenge of achieving market acceptance in a healthcare landscape dominated by established imaging modalities and entrenched reimbursement practices, all of which could delay or derail revenue generation even if technical performance is validated, particularly given the company’s dependence on third parties for development, manufacturing, and distribution, which introduces execution risk beyond its direct control.
The company’s reliance on a digital asset treasury as a capital management strategy introduces material and often overlooked risks, including exposure to cryptocurrency volatility, potential classification as an investment company under the Investment Company Act of 1940, and the risk that shifts in regulatory, accounting, or tax treatment could adversely affect the value or usability of these holdings, as explicitly noted in its filings, with the $2.4 million in digital assets representing a significant portion of its total capital base yet carrying inherent instability that could evaporate quickly during market downturns, leaving the company with even fewer operational resources than its already precarious cash position suggests.

ENDRA Life Sciences faces severe near-term liquidity constraints that threaten its ability to sustain operations long enough to achieve commercialization, with only $356,000 in cash and cash equivalents as of March 31, 2026, representing less than four months of operating cash burn at the Q1 2026 run rate of approximately $1.1 million per quarter, a situation exacerbated by the company’s history of recurring losses and limited commercial experience, which raises substantial doubt about its capacity to obtain adequate financing on favorable terms without significant dilution or restrictive covenants that could impair shareholder value.
Despite promising clinical validation data, ENDRA’s TAEUS Liver technology remains subject to significant regulatory and commercialization risks, including the potential for delays or changes in FDA requirements, the uncertainty of obtaining and maintaining CE mark certifications, and the challenge of achieving market acceptance in a healthcare landscape dominated by established imaging modalities and entrenched reimbursement practices, all of which could delay or derail revenue generation even if technical performance is validated, particularly given the company’s dependence on third parties for development, manufacturing, and distribution, which introduces execution risk beyond its direct control.
The company’s reliance on a digital asset treasury as a capital management strategy introduces material and often overlooked risks, including exposure to cryptocurrency volatility, potential classification as an investment company under the Investment Company Act of 1940, and the risk that shifts in regulatory, accounting, or tax treatment could adversely affect the value or usability of these holdings, as explicitly noted in its filings, with the $2.4 million in digital assets representing a significant portion of its total capital base yet carrying inherent instability that could evaporate quickly during market downturns, leaving the company with even fewer operational resources than its already precarious cash position suggests.

Peer Comparison

Companies in the Diagnostics & Research

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	WAT	Waters Corp /De/	31,055.11 Bn	69,126.88	8,236.16	4.86 Bn
2	TMO	Thermo Fisher Scientific Inc.	191.02 Bn	27.63	4.23	43.16 Bn
3	DHR	Danaher Corp /De/	137.16 Bn	37.32	5.54	18.48 Bn
4	IDXX	Idexx Laboratories Inc /De	42.82 Bn	39.09	9.63	0.83 Bn
5	NTRA	Natera, Inc.	39.09 Bn	-172.71	15.63	0.02 Bn
6	A	Agilent Technologies, Inc.	37.61 Bn	26.60	5.20	0.30 Bn
7	IQV	Iqvia Holdings Inc.	34.23 Bn	35.84	2.06	15.83 Bn
8	ILMN	Illumina, Inc.	28.14 Bn	32.98	6.40	1.49 Bn

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password